{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:49:55Z","timestamp":1790142595409,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004721","name":"University of Tokyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K07168"],"award-info":[{"award-number":["22K07168"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018502","name":"Kanazawa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018502","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016589","name":"Tokyo Metropolitan Institute of Medical Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016589","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108275","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:26:43Z","timestamp":1780327603000},"page":"108275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting the transcriptional coactivator p300\/CBP in cancer: Mechanistic insights and translational implications for osteosarcoma"],"prefix":"10.1016","volume":"230","author":[{"given":"Tatsuya","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Kamikubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108275_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ng1966","article-title":"Distinct chromatin signatures of transcriptional promoters and enhancers","volume":"39","author":"Heintzman","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2026.108275_bib4","doi-asserted-by":"crossref","first-page":"21931","DOI":"10.1073\/pnas.1016071107","article-title":"Histone H3K27ac separates active from poised enhancers","volume":"107","author":"Creyghton","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108275_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","article-title":"Simple combinations of lineage-determining transcription factors prime cis-regulatory elements","volume":"38","author":"Heinz","year":"2010","journal-title":"Mol. Cell."},{"key":"10.1016\/j.phrs.2026.108275_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nature09692","article-title":"A unique chromatin signature uncovers early developmental enhancers in humans","volume":"470","author":"Rada-Iglesias","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108275_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1101\/gad.14.13.1553","article-title":"CBP\/p300 in cell growth, transformation, and development","volume":"14","author":"Goodman","year":"2000","journal-title":"Genes. Dev."},{"key":"10.1016\/j.phrs.2026.108275_bib10","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1242\/jcs.114.13.2363","article-title":"p300\/CBP proteins: HATs for transcriptional bridges and scaffolds","volume":"114","author":"Chan","year":"2001","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.phrs.2026.108275_bib11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bcp.2004.03.045","article-title":"CBP and p300: HATs for different occasions","volume":"68","author":"Kalkhoven","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108275_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/384641a0","article-title":"The CBP co-activator is a histone acetyltransferase","volume":"384","author":"Bannister","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108275_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0092-8674(00)82001-2","article-title":"The transcriptional coactivators p300 and CBP are histone acetyltransferases","volume":"87","author":"Ogryzko","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib14","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/cr500452k","article-title":"Protein lysine acetylation by p300\/CBP","volume":"115","author":"Dancy","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2026.108275_bib15","first-page":"469","article-title":"Target structure-guided discovery of a small molecule that blocks the p53\u2013p300 interaction","volume":"10","author":"Sachchidanand","year":"2006","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.108275_bib16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.molmed.2010.09.002","article-title":"p53 post-translational modification: deregulated in tumorigenesis","volume":"16","author":"Dai","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2026.108275_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1105166","article-title":"Stat3 dimerization regulated by reversible acetylation","volume":"307","author":"Yuan","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108275_bib18","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/sj.onc.1207118","article-title":"p300\/CBP and cancer","volume":"23","author":"Iyer","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2026.108275_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.chembiol.2010.03.006","article-title":"Identification of a selective inhibitor of the p300\/CBP histone acetyltransferase domain","volume":"17","author":"Bowers","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108275_bib20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/1535-7163.MCT-12-0930","article-title":"Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents","volume":"12","author":"Yang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2026.108275_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108275_bib22","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.1021\/ja412434f","article-title":"Discovery and optimization of small-molecule ligands for the CBP\/p300 bromodomains","volume":"136","author":"Hay","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.108275_bib23","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","article-title":"Generation of a selective small-molecule inhibitor of the CBP\/p300 bromodomain","volume":"75","author":"Picaud","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108275_bib24","first-page":"1102","article-title":"Bromodomain inhibition of the coactivators CBP\/EP300 elicits anti-proliferative effects in cancer models","volume":"6","author":"Conery","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108275_bib25","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2018.07.041","article-title":"Enhancer activity requires CBP\/P300 bromodomain-dependent histone H3K27 acetylation","volume":"24","author":"Raisner","year":"2018","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108275_bib26","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","article-title":"Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734","volume":"4","author":"Gaudio","year":"2020","journal-title":"Blood Adv."},{"issue":"503\u2013514","key":"10.1016\/j.phrs.2026.108275_bib27","article-title":"Targeted degradation of CBP and p300 by a PROTAC. Cell","volume":"28","author":"Vannam","year":"2021","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108275_bib28","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1021\/acs.jmedchem.3c01789","article-title":"CBPD-409: an orally bioavailable CBP\/p300 degrader","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108275_bib29","article-title":"A peptide PROTAC targeting p300\/CBP","volume":"105","author":"Zhang","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.phrs.2026.108275_bib30","unstructured":"ClinicalTrials.gov. Study to evaluate CCS1477 (inobrodib) in haematological malignancies. NCT04068597."},{"key":"10.1016\/j.phrs.2026.108275_bib31","unstructured":"ClinicalTrials.gov. A study of CCS1477 in subjects with advanced solid tumours and lymphoma. NCT03568656."},{"key":"10.1016\/j.phrs.2026.108275_bib32","article-title":"Targeting epigenetics in sarcomas","volume":"86","author":"Italiano","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2026.108275_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2026.108275_bib34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108275_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","article-title":"Structural variations contribute to tumorigenesis in pediatric osteosarcoma","volume":"7","author":"Chen","year":"2014","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108275_bib36","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"MAPIE versus MAP in osteosarcoma (EURAMOS-1)","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.108275_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108275_bib38","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma treatment strategies","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108275_bib39","first-page":"273","article-title":"Enhancer reprogramming in sarcoma","volume":"23","author":"Bakhshinyan","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108275_bib40","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108275_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2025.8880","article-title":"Antitumor effect of curcumin analog targeting p300 in osteosarcoma","volume":"53","author":"Tatsumi","year":"2025","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2026.108275_bib42","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nsmb.2642","article-title":"Structure of the p300 catalytic core and implications for chromatin targeting and HAT activity","volume":"20","author":"Delvecchio","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.phrs.2026.108275_bib43","first-page":"11308","article-title":"CREB-binding protein and p300 are homologous coactivators with distinct transcriptional functions","volume":"95","author":"Xu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108275_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.18632\/aging.100453","article-title":"Is histone acetylation the most important physiological function for CBP and p300","volume":"4","author":"Bedford","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.phrs.2026.108275_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41580-018-0081-3","article-title":"Functions and mechanisms of non-histone protein acetylation","volume":"20","author":"Narita","year":"2019","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2026.108275_bib46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108275_bib48","first-page":"1375","article-title":"Oncogene regulation by super-enhancers in leukemia","volume":"346","author":"Mansour","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108275_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cell.2010.03.030","article-title":"c-Myc regulates transcriptional pause release","volume":"141","author":"Rahl","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2012.10.012","article-title":"Revisiting global gene expression analysis","volume":"151","author":"Lov\u00e9n","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cell.2017.02.007","article-title":"A phase separation model for transcriptional control","volume":"169","author":"Hnisz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3958","article-title":"Coactivator condensation at super-enhancers links phase separation and gene control","author":"Sabari","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108275_bib54","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cell.2018.10.042","article-title":"Transcription factors activate genes through phase separation","volume":"175","author":"Boija","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib55","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1535-7163.MCT-11-0182","article-title":"Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in prostate cancer cell lines","volume":"10","author":"Santer","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2026.108275_bib56","doi-asserted-by":"crossref","first-page":"51163","DOI":"10.1074\/jbc.M409024200","article-title":"Curcumin inhibits p300\/CBP histone acetyltransferase activity","volume":"279","author":"Balasubramanyam","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108275_bib57","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","article-title":"Discovery of CPI-1612: a potent EP300\/CBP histone acetyltransferase inhibitor","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.108275_bib58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1097-2765(03)00528-8","article-title":"Structural mechanism of acetyl-lysine recognition by bromodomains","volume":"13","author":"Mujtaba","year":"2004","journal-title":"Mol. Cell."},{"key":"10.1016\/j.phrs.2026.108275_bib59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0014-5793(01)03309-9","article-title":"Bromodomain: an acetyl-lysine binding domain","volume":"513","author":"Zeng","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2026.108275_bib60","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108275_bib61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in cancer biology and therapy","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108275_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108275_bib63","unstructured":"ClinicalTrials.gov. Dual BET and CBP\/p300 inhibitor EP31670 in advanced solid tumors and hematologic malignancies. NCT05488548."},{"key":"10.1016\/j.phrs.2026.108275_bib64","doi-asserted-by":"crossref","first-page":"15936","DOI":"10.1038\/ncomms15936","article-title":"Genomic rearrangements in osteosarcoma","volume":"8","author":"Behjati","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108275_bib65","unstructured":"ClinicalTrials.gov. A study of CPI-1612 in advanced solid tumors. NCT04606446."},{"key":"10.1016\/j.phrs.2026.108275_bib66","first-page":"327","article-title":"Histone acetylation regulates DNA damage response","volume":"2","author":"Ogiwara","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108275_bib67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrc.2016.62","article-title":"The role of enhancers in cancer","volume":"16","author":"Sur","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108275_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2019.02.014","article-title":"Super-enhancers in cancer","volume":"199","author":"Thandapani","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2026.108275_bib69","doi-asserted-by":"crossref","first-page":"17921","DOI":"10.1073\/pnas.1317023110","article-title":"Chromatin stretch enhancer states drive cell-specific gene regulation","volume":"110","author":"Parker","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108275_bib70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-resolved analysis of the CBP\/p300 acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib71","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrm3841","article-title":"The growing landscape of lysine acetylation links metabolism and cell signalling","volume":"15","author":"Choudhary","year":"2014","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2026.108275_bib72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib73","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies BRD4 as a therapeutic target in acute myeloid leukemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108275_bib74","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108275_bib75","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108275_bib76","first-page":"130","article-title":"The essential transcriptional function of BRD4 in acute myeloid leukemia","volume":"29","author":"Roe","year":"2016","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.108275_bib77","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B-cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.108275_bib78","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-informed targeted therapy for osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108275_bib79","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1038\/ncomms9940","article-title":"Exome sequencing of osteosarcoma reveals mutation signatures","volume":"6","author":"Kovac","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108275_bib80","first-page":"143","article-title":"Osteosarcoma: current therapy and future directions","volume":"62","author":"Rainusso","year":"2015","journal-title":"Pediatr. Clin. North. Am."},{"key":"10.1016\/j.phrs.2026.108275_bib81","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nchembio.1867","article-title":"The promise and peril of chemical probes","volume":"11","author":"Arrowsmith","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108275_bib82","first-page":"364","article-title":"Probing the probes: fitness factors for small-molecule chemical probes","volume":"6","author":"Workman","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108275_bib83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:58:07Z","timestamp":1785074287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":83,"alternative-id":["S1043661826001908"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108275","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the transcriptional coactivator p300\/CBP in cancer: Mechanistic insights and translational implications for osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108275"}}